Literature DB >> 6210002

Predictive factors for bleomycin-induced pneumonitis.

P W Van Barneveld, T W van der Mark, D T Sleijfer, N H Mulder, H S Koops, H J Sluiter, R Peset.   

Abstract

Five pulmonary function tests (transfer factor for carbon monoxide, diffusing capacity of the alveolar-capillary membrane, pulmonary capillary blood volume, alveolar volume, vital capacity) were performed, and creatinine clearance was measured in 39 patients with disseminated testicular nonseminomatous tumor treated with a combination chemotherapy containing bleomycin. Eight of these patients (20.5%) developed bleomycin-induced pneumonitis (BIP). To investigate which parameter has value in predicting BIP, a discriminant analysis was performed. The combination of a low normal creatinine clearance, a decrease in vital capacity and alveolar volume without a decrease in pulmonary capillary blood volume, pointed to an increased risk. We concluded that it is worthwhile to monitor these parameters and, if necessary, to adapt the chemotherapy of a patient at risk.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6210002     DOI: 10.1164/arrd.1984.130.6.1078

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.

Authors:  Yuki Maruyama; Takuya Sadahira; Yosuke Mitsui; Motoo Araki; Koichiro Wada; Ryuta Tanimoto; Yasuyuki Kobayashi; Masami Watanabe; Toyohiko Watanabe; Yasutomo Nasu
Journal:  Med Oncol       Date:  2018-04-26       Impact factor: 3.064

Review 2.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

3.  Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

Authors:  J G Hay; P L Haslam; A Dewar; B Addis; M Turner-Warwick; G J Laurent
Journal:  Thorax       Date:  1987-05       Impact factor: 9.139

Review 4.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

5.  Postoperative acute respiratory distress syndrome in patients with previous exposure to bleomycin.

Authors:  Benjamin M Aakre; Richard I Efem; Gregory A Wilson; Daryl J Kor; John H Eisenach
Journal:  Mayo Clin Proc       Date:  2014-02       Impact factor: 7.616

Review 6.  Pulmonary fibrosis: pathogenesis, etiology and regulation.

Authors:  M S Wilson; T A Wynn
Journal:  Mucosal Immunol       Date:  2009-01-07       Impact factor: 7.313

7.  Bleomycin-induced lung injury in the rat: effects of the platelet-activating factor (PAF) receptor antagonist BN 52021 and platelet depletion.

Authors:  T W Evans; R J McAnulty; D F Rogers; K F Chung; P J Barnes; G J Laurent
Journal:  Environ Health Perspect       Date:  1990-04       Impact factor: 9.031

8.  Long-term toxicity of chemotherapy for testicular cancer--the cost of cure.

Authors:  N S Stuart; C M Woodroffe; R Grundy; M H Cullen
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

9.  Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect.

Authors:  S Sleijfer; T W van der Mark; H Schraffordt Koops; N H Mulder
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

10.  The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD.

Authors:  Adam F Binder; Sonia Rai; Amir Steinberg
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.